anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to two ATP diphosphohydrolases (ATPDase enzymes) isolated from bovine aorta and pig pancreas, which enzymes have a molecular weight for their catalytic unit of about 78 and 54 Kilodaltons, respectively. A first process for obtaining a highly purified ATPDase is also an object of the present invention. This process has been successfully applied to the purification of both the pancreatic and the aorta enzymes and is deemed to work in the purification of any ATPDase. For both sources of enzymes, the process allows the specific activity of the enzyme to be increased by at least 10,000 fold when compared to the activity retrieved in the crude cell homogenates. The novel process involves an ion exchange chromatography step, a separation on an affinity column, followed by an electrophoresis under non-denaturing conditions. The two enzymes purified by this process (aortic and pancreatic) are glycosylated and, when deglycosylated, have molecular weights shifted to about 56 and 35 Kdaltons, respectively. Partial amino acid sequences have been obtained for each enzyme. The partial sequences appear highly homologous with a human lymphoid cell activation antigen named CD39. An antibody directed against the porcine pancreatic enzyme cross-reacts with a protein present in endothelial cell lines and in bovine aorta (78 KDa). The high degree of homology of the pancreatic and aortic enzymes with CD39 and their cross-reactivity are indications that both enzymes are related. The pancreatic enzyme completely lacks the first 200 amino acids of CD39, which means the ATPDase activity is comprised between residues 200 and 510 of CD39. Since this is the first time that a sequence is assigned to ATPDases, a second new process for producing ATPDases by recombinant technology can also be used. Therefore a second new process for producing an ATPDase using the CD39-encoding nucleic acid or part or variant thereof is also described.
Tolcapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT).

In mammals, COMT is distributed throughout various organs. The highest activities are in the liver and kidney. COMT also occurs in the heart, lung, smooth and skeletal muscles, intestinal tract, reproductive organs, various glands, adipose tissue, skin, blood cells and neuronal tissues, especially in glial cells. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing the metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery.

The precise mechanism of action of tolcapone is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that these sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease in patients as well as increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodopa. Tolcapone enters the CNS to a minimal extent, but has been shown to inhibit central COMT activity in animals.
The present invention discloses a technology of making a Rukang tablet into a Rukang dispersible tablet. The technology adopts the prescription of the Rukan tablet and adds supplementary materials so that the Rukang dispersible tablet is prepared. The Rukang dispersible tablet with the advantages of tablets and granular formulations has the characteristics of quick dispersion, good dispersed state and quick drug dissolution, and can take effect quickly. The Rukang dispersible tablet can be taken after dispersed in warm boiled water (dispersed in 3 minutes) or taken directly. The present invention has the advantages of easy portability, easy use, reliable curative effect, etc; besides, the present invention has conspicuous curative effect on cyclomastopathy, can be ingested, chewed, sucked or taken after dispersed in water, and is particularly suitable for old people and patients who have difficulty in ingestion. The production process of the Rukang dispersible tablet is generally the same as the production processes of common tablets, and specific requirements and additional devices are not needed, thereby lowering production cost.
PROBLEM TO BE SOLVED: To obtain an agent comprising a hydroxystilbene and capable of stimulating skin desquamation and regeneration without causing unpleasant piquant pain, stretching cramping feeling, flush and redness. SOLUTION: This agent comprises at least one kind of hydroxystilbene (preferably, 3,4',5-trihydroxystilbene or the like) preferably in an amount of 0.001-10% of the total weight, and is useful for stimulating skin desquamation and/or regeneration, and/or resisting endogenous and/or exogenous skin aging. The agent is used preferably in a shape of emulsion, aqueous solution which is optionally gelatinized, lotion such as two layer lotion, cream, milk or foam. The agent optionally contains an oil phase comprising an animal, plant, mineral, silicone, fluorinated and/or synthetic oil as a base. The oil phase further optionally contains a makeup-removing oil (e.g. an fatty acid ester).
The present invention relates to a cosmetic treatment method comprising the steps of providing a foamable composition, forming a foam from said foamable composition on release from a pressurized container, drying said foam wherein the foam does not disappear upon drying, wherein said foam is applied or generated between the scalp and the scalp hair and thereby raising the hair. Preferred methods are hair styling methods, methods of permanently shaping the hair, methods of coloring hair and hair care methods. The dried foam can be used as mechanical support for raising the hair, especially as substitutes for conventional hair curlers, rollers, pins, hair clips or hairgrips. The invention also relates to devices for use in said method. The devices comprise a composition capable of forming a foam that can be dried; and an aerosol container equipped with a foaming device. The composition comprises at least 1% by weight, based on the composition without propellants, of a zwitterionic surfactant or a surfactant mixture comprising at least one zwitterionic surfactant, at least one hair fixing polymer, at least 20% by weight, based on the total composition, of at least one propellant and water. Preferred zwitterionic surfactants are surfactants containing a betaine or a sultaine structure.
The invention provides a traditional Chinese medicine used after an operation for promoting wound healing. The medicine comprises raw materials of, by weight: 6 to 10 parts of anderson cirrhopetalum herb, 2 to 4 parts of lepisori, 3 to 5 parts of broadleaf holboellia fruit, 1 to 2 parts of shinyleaf pricklyash root, 10 to 12 parts of vaiante spleenwort herb, 6 to 8 parts of pteris wallichiana agardh, 1 to 3 parts of pakchoi dried stem and leaf, 1 to 3 parts of medicinal evodia immature fruit, 4 to 6 parts of clove, 5 to 7 parts of rice bean, 4 to 6 parts of panax notoginseng, 2 to 4 parts of Chinese pulsatilla, 1 part of eupolyphaga sinensis, 8 to 10 parts of eclipta prostrate, 1 to 3 parts of black cicada slough, 2 to 4 parts of puff-ball, and 3 to 5 parts of angelica archang lica. The trasditional Chinese medicine is advantaged in that: the cost is low, and the curative effect is good. With the medicine, wounds can heal rapidly; pains can be reduced; infections can be prevented; and bleeding, suppuration, tissue fluid bleeding, and inflammations are avoided. With the medicine, injection and transfusion are not required. The medicine is characterized in fast and substantial effect. With the medicine, pains and economic burdens of patients are greatly reduced.
FIELD: organic chemistry, chemical technology. SUBSTANCE: invention relates to method for preparing 8-methoxyquinolone carboxylic acids of the general formula (I)  . Method involves interaction of 8-halogen-3-quinolone carboxylic acids with metal alcoholates in the presence of alcohols. Process is carried out at temperature from 20 C to solvent boiling point under atmosphere pressure using aliphatic or cycloaliphatic ester as a solvent followed by isolation of the end product as free form or salt and, if necessary, its treatment. Invention provides the development of method for preparing 8-methoxyquinolone carboxylic acids allowing reducing reaction time, to carry out working under atmosphere pressure and providing complete conversion and simple preparing reaction mixture also. EFFECT: improved and simplified preparing method. 19 cl, 2 ex
PROBLEM TO BE SOLVED: To provide a method for treating a cancer by using arginine deiminase (ADI).SOLUTION: The present invention relates to a method for treating a cancer by using arginine deiminase, in particular, pegylated arginine deiminase. In one aspect, provided is a compound which is used for treating leukemia, and which includes the arginine deiminase covalently linked with polyethylene glycol via a linking group. In another aspect, the leukemia is acute myeloid leukemia. In another aspect, the leukemia is recurrent acute myeloid leukemia. In another aspect, the leukemia is not lymphocytic leukemia or chronic myeloid leukemia. In an additional aspect, provided is a compound which is used for treating a cancer of a patient, and which includes a combination of an autophagy inhibitor and the arginine deiminase covalently linked with the polyethylene glycol via the linking group. The cancer is pancreatic cancer, sarcoma, or small cell lung cancer.
The invention discloses a proved recipe for treating heatstroke. Heatstroke is mainly caused by insolation and high-temperature operation in burning sun. The initial symptoms include dizziness, headache, palpitation, weakness, thirst and nausea, and disappear after short break. For a severe situation, the body temperature can exceed 40 DEG C, and the symptoms such as flushed and hot face, dry skin without sweat, muscle twitch, even obnubilation and coma occur. When the proved recipe is used for treating heatstroke, the Chinese herbal medicines are adopted as raw materials and processed into juice by a traditional decoction method for oral taking; and the medicine is applied according to the symptoms based on the etiopathogenesis, and any toxic or side effect is avoided. The proved recipe is applicable to dizziness and thirst caused by heatstroke, faint, unconsciousness, fever, fatigue, spontaneous sweating, upset, abdominal pain and diarrhea and chest distress and vomiting, and the treatment effect is good; the proved recipe for heatstroke is subjected to years of repeated study; based on the healing of hundreds of patients and according to the clinical observation on the curative effect, the total effective rate reaches 94%, and the cure rate reaches 91%; the proved recipe for heatstroke can resolve summer heat and reinforce healthy qi, has a perfect effect in cooling and dispersing heat and calming the nerves, and can effectively activate the immune functions of a human body; and moreover, the treatment course is short, the effect is fast, and the consolidation performance is good.
The problems related to blood glucose in non-endocrine departments are becoming more and more serious.Glucose control level is closely related to the prognosis and cost of inpatients. Insulin therapy is the mainstream glucose-lowering program for hospital glucose management. Intelligent insulin dose calculation software based on fingertip glucose monitoring is born in response to the situation. A new generation of continuous blood glucose monitoring technology compared with traditional monitoring technology provides more abundant blood sugar change information.The development of the continuous glucose monitoring technology espcially in blood sugar change trend arrow information, the intelligent insulin dose adjustment sequence based on WeChat program is developed. We plan to carry out a randomized controlled study on patients receiving insulin therapy, in which the insulin dose is adjusted according to the information of four blood glucose monitoring points (before meals and before bed), and randomly divided into two groups, one group is adjusted according to the experience of clinicians, the other group is adjusted according to Wechat program, and glucose monitoring is continued for 1 week. bBood glucose control index of TIR , and the incidence of hypoglycemia and hyperglycemia, hospitalization days and cost was observed. This study ihas great clinical value.
60 septic shock patients requiring norepinephrine to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation will be enrolled in the study. After an initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75 mmHg and normovolemia, patients will be randomly allocated to be treated with either a) intravenous administration of terlipressin 1 µg∙kg-1∙h-1 for 6 hrs, b) intravenous administration of arginine vasopressin 0.04 UI∙min-1 for 6 hrs, c) intravenous administration of terlipressin bolus dose of 0.5 mg (each n = 20). In all groups open label norepinephrine will be additionally administered to maintain a mean arterial pressure (MAP) between 65 and 75 mmHg, if necessary. Data from right heart catheterization and sublingual microvascular network will be obtained just before randomization (baseline) and then after 6 hours in the vasopressin, terlipressin infusion and terlipressin bolus groups.

The sublingual microvascular network will be studied using the sidestream dark field (SDF)imaging. The device will be applied on the lateral side of the tongue, in an area approximately 2-4 cm from the tip of the tongue. Sequences of 10 secs from eight adjacent areas will be recorded on disk using a personal computer. These sequences will be later analyzed by an investigator blinded to the patient's diagnosis and therapy.
Schizophrenia is a chronic disease with deficit in social interaction and lost of autonomy in daily life. Negative symptoms as blunted affect, avolition, social deficit and anhedonia and cognition were prognosis and functioning key's factors. Psychotropic medications have shown only poor effect to improve negative symptoms and cognition as attention, memory and cognitive flexibility. So, cognitive remediation programs were developped to focus cognitive disorders. The IPT (Integrated Psychological Treatment) is one of the most complete program with modules on cognitive and social abilities. The aim of this study is to evaluate the efficacy of IPT+ program to improve autonomy capacities of long stay inpatients suffering from schizophrenia 6 at the end of the program The secondary objectives are to evaluate autonomy 6 months after the program, to evaluate the efficacy of the program on negative symptoms, quality of life, cognitive functions, social cognition and duration of hospitalisation.

This study propose a randomised controlled study with 2 arms, with blind evaluation to compare the IPT+ versus treatment as usual (TAU). The follow up will be 6 month for the With IPT+ this study will improve autonomy capacities for patients suffering from deficit schizophrenia and allowed patients to go out hospital earlier than before.
To provide information for encouraging a health care target person to take an action conforming to a medical worker's instruction.SOLUTION: A health care support device of an embodiment has a setting unit, an acquisition unit, a calculation unit, a correction unit, and a display control unit. The setting unit receives input of target action information related to a target action of a health care target person and sets the target action information. The acquisition unit acquires biological information of the target person. The calculation unit calculates a first index indicating the state of health of the target person based on the biological information. The correction unit calculates a second index obtained by correcting the first index based on the target action information. The display control unit controls a method for displaying the second index.SELECTED DRAWING: Figure 1
Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety of fluorescent contrast agents, such as fluorescein sodium, methylene blue, indocyanine green and then undergo hematoxylin and eosin processing.
Acute flaccid myelitis (AFM) is a serious neurologic condition primarily affecting children; AFM can cause acute respiratory failure and permanent paralysis. AFM is a rare but known complication of various viral infections, particularly those of enteroviruses (EVs). Increases in AFM cases during 2014, 2016, and 2018 were associated with EV-D68 infection. This report examines trends in confirmed AFM cases during 2018-2022 and patients' clinical and laboratory characteristics. The number of AFM cases was low during 2019-2022 (28-47 cases per year); the number of cases remained low in 2022 despite evidence of increased EV-D68 circulation in the United States. Compared with cases during the most recent peak year (2018), fewer cases during 2019-2021 had upper limb involvement, prodromal respiratory or febrile illness, or cerebrospinal fluid pleocytosis, and more were associated with lower limb involvement. It is unclear why EV-D68 circulation in 2022 was not associated with an increase in AFM cases or when the next increase in AFM cases will occur. Nonetheless, clinicians should continue to suspect AFM in any child with acute flaccid limb weakness, especially those with a recent respiratory or febrile illness.
Chronic kidney disease (CKD) is highly prevalent affecting 14% of the U.S. population leading to substantial morbidity and reduced quality of life. Older adults with CKD identify maintenance of functional independence as their top priority. Skeletal muscle health is critical for mobility and an underrecognized target of metabolic acidosis (MA) and protein energy wasting in CKD. Skeletal muscle endurance provides a window into muscle metabolic health and muscle quality. Muscle mitochondrial metabolism is central to muscle and walking endurance providing energy from carbohydrates and fats to power repeated muscle contraction. Investigators showed metabolic acidosis and muscle adiposity as the major determinants of muscle mitochondrial function.

Metabolic acidosis (MA) is long believed to be the main mechanism leading to skeletal muscle wasting and peripheral insulin resistance in CKD. Skeletal muscle mitochondrial metabolism is considered a principal determinant of peripheral insulin sensitivity and muscle quality, but little is known of the impact of MA on muscle mitochondrial function. Muscle mitochondrial dysfunction leads to defective lipid metabolism augmenting adiposity and lipotoxic intermediates resulting in insulin resistance, low endurance, and muscle atrophy. Using in vivo 31Phosphorus Magnetic Resonance Spectroscopy (31P MRS) investigators showed that the presence and severity of CKD is strongly associated with impaired muscle mitochondrial capacity to generate ATP translating into poor walking endurance. Investigators also showed MA and muscle adiposity are the major determinants of muscle mitochondrial function. Despite the importance of mitochondrial function to muscle health, it is unknown if treatment of MA benefits muscle mitochondrial function, adiposity or endurance in CKD.

The proposed project will use precise, in vivo 31P MRS and gold-standard testing of peripheral insulin sensitivity by hyperinsulinemic euglycemic clamp to probe the pathophysiology of MA and low endurance in a clinical trial of alkali therapy in CKD and MA. We will compare sodium bicarbonate to placebo in a multicenter randomized, cross-over trial design in 80 persons with moderate-severe CKD and MA. First, the efficacy of 4-months of alkali therapy will be tested comparing sodium bicarbonate versus placebo on muscle metabolic health in a randomized crossover trial in MA. Second, we will test the efficacy of 4-months of alkali therapy comparing sodium bicarbonate versus placebo on improving physical endurance in MA. The rationale is that identification of therapeutic targets for low physical endurance will inform the development of pharmacologic interventions. Long term, it is expected that strategies treating MA will improve exercise tolerance enabling effective engagement in lifestyle interventions improving quality of life in CKD.
It is intended that the specific detection and individualized approach to neuromuscular deficiencies will decrease the prevalence of injuries and accidents and therefore, the performance of training basketball players will be improved. The purpose of this study was to evaluate and detect federated youth basketball players' (under 12 years until under 17 years) neuromuscular deficits in mobility, stability and landing technique in static and dynamic situations similar to simulate the most important actions of basketball demands.

This cross-sectional study was conducted from October 2018 to May 2019. A total of 778 basketball players were selected for the present study. In order to evaluate this specific tests and trials will be carried out on different teams from various clubs in the categories from under 12 years (U12) to under 17 (U17), both male and female. The evaluations will consist of a static physical measures and a dynamic one. These will be conducted throughout the season. Inclusion criteria were: age \> 12 years and \<18 years at testing, and to be actively competing during the study. Subjects were excluded if they had suffered any injury in lower limbs before the screening; presented any injury (overuse or acute) at the time of testing or if they suffered any oncological, psychological and/or psychiatric illnesses, or if they did not attend on the day of the assessment. The main outcomes were ankle joint dorsiflexion was analyzed with Weight-bearing Dorsiflexion Test; monopodial ankle stability was analyzed with Single Leg Balance Test. Dynamic lower extremity valgus was analyzed with Single Leg Squat Test, Modified Tuck Jump Test, Single Leg Squat Test and Hurdle Step Test were used to evaluate also Lumbopelvic stability and dynamic postural control. Neuromuscular deficits during continuous tuck jumps, landing technique flaws and Plyometric Technique were analyzed with Modified Tuck Jump Test. All these tests are scientifically validated for this purpose. All players were familiar with the procedures of all test before. Testing was performed in the same day, in the same order, at the same time of the day (18:00-20:00).
Treatment consists of Interferon, given as a sub-cutaneous injection, 3 times per week for 4 weeks, 20 mg Retinoic Acid tablets, 2 times a day for 30 days. starting from the first day of radiation.